Citations 2
P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Joffe, E., Nowakowski, Grzegorz S. , Lunning, Matthew A. , Ramchandren, Radhakrishnan , Li, C.-C., Zhou, Li , Martinez, Elizabeth , Roemeling, R. von, Earhart, Robert H., McMahon, Meaghan, Isufi, Iris, Leslie, Lori A. , Joffe, Erel , Tun, Han W. , Rosenthal, Allison
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1011-1012
AN OPEN‐LABEL TRIAL OF ORAL CA‐4948 AN IRAK4 INHIBITOR COMBINED WITH IBRUTINIB IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
Ramchandren, Radhakrishnan , Nowakowski, Grzegorz S. , Lunning, M., Mead, Monica , Martinez, Elizabeth , Roemeling, R. von, Leslie, Lori A. , Joffe, Erel , Rosenthal, Allison , Tun, Han W. , Lunning, Matthew A.
Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available